DrugPatentWatch Database Preview
Details for Biologics License Application: 125085
» See Plans and Pricing
Summary for BLA: 125085
Tradename: | AVASTIN |
Applicant: | Genentech |
Ingredient: | bevacizumab |
Patents: | 1041 |
Approval Date: | Feb 26, 2004 |
Suppliers: see list | 1 |
Pharmacology for BLA: 125085
US Patents for BLA: 125085
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Genentech | AVASTIN | bevacizumab | VIAL; INTRAVENOUS | 125085 | 001 | 2004-02-26 | Start Trial | IMMATICS BIOTECHNOLOGY GMBH (Tuebingen, DE) | 2035-03-27 | RX | search | |
Genentech | AVASTIN | bevacizumab | VIAL; INTRAVENOUS | 125085 | 001 | 2004-02-26 | Start Trial | SAMSUNG LIFE PUBLIC WELFARE FOUNDATION (Seoul, KR) | 2032-09-12 | RX | search | |
Genentech | AVASTIN | bevacizumab | VIAL; INTRAVENOUS | 125085 | 001 | 2004-02-26 | Start Trial | IMMATICS BIOTECHNOLOGIES GMBH (Tuebingen, DE) | 2035-12-11 | RX | search | |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |